Peptide Vaccine Manufacturing | Interview with Dr. Mimoun Ayoub of CordenPharma

"The concept of designing immunomodulating peptide cocktails and trigger the immune response has been mainly initiated by biotech companies who owns more than 80% of the current cancer vaccine pipeline."

In a recent interview with TIDES, Mimoun Ayoub, Ph.D., Director, Global Peptides & Injectables Platform, CordenPharma, Switzerland, shifts the focus towards the topics that will be addressed in his talk at the upcoming TIDES event. In his talk he will be examining the peptide vaccines that are designed to activate B-cells and killer T-cells to recognize cancer cells as foreign agents. Cancer cells have surface protein modifications such as phosphorylations and glycosylations that differentiate them from healthy cells. The peptide epitopes used are usually fragments from these modified proteins. These "cocktails" of peptide fragments can be further engineered to increase their immune activity and plasma half-life by constraining the peptide backbone through introduction of cyclization or non-natural amino acids in the sequence. The production and analytical challenges related to cocktail peptide vaccines will be discussed.

In the interview, Dr. Ayoub also addresses:

• The role peptide vaccines play in the in the development of novel cancer therapies
• Regulatory challenges during the development and manufacturing of peptide vaccine "cocktails"
• Future delivery methods for administering peptide vaccines

Access the complete interview

To learn more from Dr. Ayoub, join him at IBC's 18th Annual TIDES event this May in Long Beach, CA where he will be chairing the Peptide Chemistry Manufacturing and Controls track as well as speaking in a session titled "Peptide Vaccine Manufacturing : Drug Substance and Drug Product CMC Challenges" Download the brochure to access the complete agenda and speaking faculty. 


Register for TIDES now and save $500 - To activate your savings, use the code B16180BLOG100  

Share this article with your social network, just click below to share now!

Share |

Attend IBC's Immuno-Oncology Conference in Alexandria, VA for FREE as a Guest Blogger

Earn a complimentary all-access pass to Immuno-Oncology conference by serving as a Guest Blogger at the event. As a Guest Blogger, you’ll have access to the Immuno-Oncology event’s comprehensive agenda attracting the best insights from around the world, right in Alexandria, VA in September.

Immuno-Oncology Conference

September 30-October 1, 2015

Hilton Alexandria Mark Center, Alexandria, VA

We are looking for an industry expert to be the face of the IBC's Immuno-Oncology social media campaign. The premise is to provide immuno-oncology and cancer immunotherapies - related articles, whitepapers, and overall original content.

Some of the topics of the conference are: 

• cancer vaccines;
• T-cell therapy;
• agnostic antibodies;
• combination therapies and others.

What You get:

• FREE pass to IBC's Immuno-Oncology conference (valued up to $1,999);
• Extensive social learning activities;
• Exclusive access to a networking community in the industry of your interest!

You also have a chance to GAIN exposure through our five health related-blogs with over 2000 unique visitors monthly each and more than 20 healthcare LinkedIn groups.

Learn more about the IBC's Immuno-Oncology conference event by visiting the website:

Interested and want to learn more about this opportunity please contact Amanda Caterina at acaterina@iirusa.com or directly at 646-895-7339.

We hope to have you join us in Alexandria!

Cheers,

The IBC's Immuno-Oncology Team

@ibcusa

#Immuno15

Visit the website: http://www.ibclifesciences.com/ImmunoOncology/overview.xml

Future of Biopharma Blog http://futurebiopharma.blogspot.com/

Share this article with your social network, just click below to share now!

Share |

ADC emerge as leading cancer treatment option

Antibody Drug Conjugates (ADCs) are an ideal way to target cancer cells while missing the cancer cells.  Two ADCs have jumped to the top of the treamtent list -brentuximab vedotin which treats lymphomia and ado-trastuzumab emtansine which treats breast cancer.

As their success grows, and more therapies using this technology are being developed, finding safe manufacturing methods for ADCs has posed to be the next big challenge. According to BioProcess International, there are four key factors of an ADC that must be in tact to produce a working ADC: the antigen, the targeting antibody, the linker, and the payload. In order to create more drugs at a larger scale, researchers are focusing development methods that reduce heterogeneity and ways to create site-specific conjugations.  Not only that, but finding these two things are some of the next key challenges for scientists:

• -How to increase clinical impact for tumors that display heterogeneous expression of a target antigen
• -How to improve outcomes for those ADCs that show promising early efficacy before tumors develop resistance.

Read the full article here.  

What do you see as the next big breakthrough in antibody drug conjugate therapy?

This year at BDP Week, we'll have an afternoon dedicated to New Modalities and Next Generation ADCs – Challenges in Development and Production with presentations from companies including MedImmune, Sutro Biopharma Inc. and CytomX Therapeutics, Inc.  For more information on this session and the rest of the program, download the agenda.  As a reader of this blog, when you register to join us and mention code XB15155BLOGJP to save 20% off the standard rate.

Share this article with your social network, just click below to share now!

Share |